--- title: "RemeGen Forecasts 2025 Profit Turnaround on Surging Drug Sales and Global Licensing Deal" description: "RemeGen Co. Ltd. forecasts a profit turnaround in 2025, projecting operating revenue of approximately RMB3.25 billion, an 89% increase year-on-year, and a net profit of around RMB716 million. This imp" type: "news" locale: "en" url: "https://longbridge.com/en/news/274309164.md" published_at: "2026-01-30T12:12:19.000Z" --- # RemeGen Forecasts 2025 Profit Turnaround on Surging Drug Sales and Global Licensing Deal > RemeGen Co. Ltd. forecasts a profit turnaround in 2025, projecting operating revenue of approximately RMB3.25 billion, an 89% increase year-on-year, and a net profit of around RMB716 million. This improvement is attributed to strong sales of its biologic drugs, a global licensing deal with Vor Biopharma, and internal cost efficiencies. The company expects to shift from a loss in 2024 to profitability in 2025, enhancing its market position. The current analyst rating for RemeGen stock (HK:9995) is a Hold with a price target of HK$88.00. ### Claim 50% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an announcement. RemeGen Co., Ltd. has issued preliminary 2025 financial estimates indicating a sharp rebound in performance, with operating revenue expected to reach about RMB3.25 billion, up roughly 89% year on year, and net profit attributable to shareholders projected at around RMB716 million, compared with a substantial loss in 2024. The turnaround is driven by rapid sales growth of its core biologic drugs telitacicept and disitamab vedotin in China, a major global licensing deal granting Vor Biopharma exclusive rights to develop and commercialize telitacicept outside Greater China that boosts technology licensing income and shifts some overseas R&D costs to the partner, as well as internal cost and efficiency measures that have lowered production costs, improved gross margins and reduced sales expenses; even after excluding non-recurring gains, notably from fair-value changes of warrants tied to the licensing transaction, the company expects to move from loss to profit in 2025, signaling a significant improvement in its profitability profile and market positioning. The most recent analyst rating on (HK:9995) stock is a Hold with a HK$88.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page. **More about RemeGen Co. Ltd. Class H** RemeGen Co., Ltd. is a biopharmaceutical company based in China focused on developing and commercializing innovative biologic therapies. Its core marketed products include telitacicept and disitamab vedotin, with a growing emphasis on both domestic sales in the PRC and global partnering, particularly through out-licensing arrangements for its pipeline assets. **Average Trading Volume:** 4,652,921 **Technical Sentiment Signal:** Buy **Current Market Cap:** HK$58.65B For an in-depth examination of 9995 stock, go to TipRanks’ Overview page. ### Related Stocks - [560600.CN - Founder Fubon CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/560600.CN.md) - [159506.CN - Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF](https://longbridge.com/en/quote/159506.CN.md) - [159615.CN - China Southern Hang Seng Biotech ETF(QDII)](https://longbridge.com/en/quote/159615.CN.md) - [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md) - [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md) - [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md) - [513700.CN - Penghua CSI HK Connect Health Care Composite ETF](https://longbridge.com/en/quote/513700.CN.md) - [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md) - [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md) - [159892.CN - ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)](https://longbridge.com/en/quote/159892.CN.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) | | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/en/news/276024005.md) | | Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) | | Niowave and Novartis enter global actinium-225 Supply Agreement to advance next-generation cancer therapies | Niowave and Novartis enter global actinium-225 Supply Agreement to advance next-generation cancer therapies | [Link](https://longbridge.com/en/news/275604614.md) | | SSY Group Gets Bulk Drug Approvals for Two Products in China | SSY Group Gets Bulk Drug Approvals for Two Products in China | [Link](https://longbridge.com/en/news/275313672.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.